This Policy Review presents the International Myeloma Working Group’s clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients ...Continue Reading
This article was originally posted on Cure Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies. Cristina Gasparetto, MD: We talked about your quality of life. Sometimes patients, they listen to us as physicians, but they listen to patients more. What type of...Continue Reading
Australian patients with amyloidosis face a lottery where they may be denied effective medication depending on how strictly their physician interprets the letter of PBS rules, a haematologist has told a parliamentary inquiry. Dr Peter Mollee, head of the Myeloma Service and the Princess Alexandra Hospital Amyloidosis Centre in Brisbane, told the House of Representatives...Continue Reading
This article was originally published on NZ Herald.co.nz Do you know why you’re here? I thought I did until I was asked. I’m in a small, windowless brick room at Auckland Hospital. This starter for 10 was delivered by a man who was to become my clinical haematologist. Until that morning I had no idea...Continue Reading
This article was originally published on The Limbic Australian blood cancer patients are being denied access to life-extending drugs and treatments because of long delays and excessive regulation by the Pharmaceutical Benefits Advisory Committee (PBAC), a parliamentary inquiry has been told. Leading haematologist Professor Andrew Spencer said the registry of myeloma cases established some eight...Continue Reading
This article was originally published by Medical News Today Multiple myeloma is a type of blood cancer that affects plasma cells. Doctors use a three-step staging system to classify the severity of multiple myeloma and whether it has spread. A person may experience different types of symptoms in each stage, and survival rates will change...Continue Reading
This article was originally posted by Journal of Experimental Pharmacology Offidani et al. Journal of Experimental Pharmacology 2021:13 245–264 Offidani, Corvatta, Morè & Olivieri Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging...Continue Reading
Auckland Myeloma Patient Seminar, hosted by Myeloma New Zealand. We heard from Dr Henry Chan (Waitemata DHB), Dr Nicole Chien (Auckland DHB), Dr Ken Romeril and nursing staff from Auckland and North Shore Hospitals.Continue Reading
This article was originally posted by targeted Oncology Case: A 75-Year-Old Man with Multiple Myeloma Initial Presentation A 75-year-old man presents with worsening fatigue on exertion, pallor, and hip painPMH: osteoarthritisPE: tired appearing male, poor hand-grip strength, mild tenderness on palpation of the left hipECOG 2 Clinical workup Hb 9.8 g/dL, corrected calcium 11.9mg/dL, LDH 295U/L,...Continue Reading
This article was originally published on TheLimbic Australian experts have been ‘startled’ to discover that many patients with multiple myeloma do not receive recommended imaging and staging, sparking concerns about missed diagnoses and overtreatment of benign forms of the disease. The findings come from an analysis of real-world data of more than 2400 newly diagnosed...Continue Reading
